Allied Market Research
Loading...
0
Upcoming Allied Market Research
2021
Efavirenz Market

Efavirenz Market by Type (Single Efavirenz, Two-drug combination, Three-drug combination), Application (Adults, Children), and End User (Hospitals, Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021–2030

A14415
Pages: NA
Jan 2022 | 84 Views
   
Author(s) : NA
Tables: NA
Charts: NA
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Efavirenz Market

Request Now !

Efavirenz is an anti-HIV drug that slows down the damage to immune system and prevents occurrence of AIDS-related illnesses. It belongs to a family of drugs known as nonnucleoside reverse transcriptase inhibitors, which converts single-stranded viral RNA into a double-stranded DNA.  Efavirenz is not a cure for HIV infection but it helps to decrease amount of HIV in the body so that immune system can work better. Moreover, this lowers the chance of getting HIV complications (such as new infections and cancer) and improves quality of life. It is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission.

Market scope and structure analysis

Report Metric

Details

  Market size available for years

  2020–2030

   Base year considered

  2020

  Forecast period

  2021–2030

  Forecast units

  Value (USD)

  Segments covered

  Type, Application, End User, and Region

  Regions covered

North America (U.S. and Canada), Europe (Germany, UK, France, and the Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA)

  Companies covered

Bristol-Myers Squibb, Strides Pharma, Aurobindo Pharma, Teva, Hetero, Mylan, Macleods Pharmaceuticals, Cipla, Gilead Sciences.

 

COVID-19 scenario analysis

Lockdowns and border closures imposed to stop COVID-19 are impacting both production of antiretroviral medicines and their distribution, potentially leading to increases in their cost and to supply issues. Hence, the efavirenz market has been negatively impacted. According to the United Nations Programme on HIV and AIDS (UNAIDS), recent modelling has estimated that a six-month complete disruption in HIV treatment could lead to more than 500,000 additional deaths from AIDS-related illnesses and if services to prevent mother-to-child transmission of HIV were similarly halted for six months, the estimated increases in new child HIV infections would be 162% in Malawi, 139% in Uganda, 106% in Zimbabwe and 83% in Mozambique. The halt in the production and supply of efavirenz drugs has created crisis in the treatment of HIV infection, therefore, the efavirenz market can experience a significant growth during the forecast period.

Top impacting factors: market scenario analysis, trends, drivers and impact analysis

Prevalence of HIV infection worldwide has led to an increase in demand for effective treatment. For instance, according to the United Nations Programme on HIV and AIDS (UNAIDS), there were approximately 38 million people across the globe with HIV/AIDS in 2019. Of these, 36.2 million were adults and 1.8 million were children (<15 years old). It is estimated that 1.7 million individuals worldwide acquired HIV in 2019, marking a 23% decline in new HIV infections since 2010. However, progress on prevention of HIV transmission remains far too slow, with estimated total number of new infections in 2019 more than three times higher than UNAIDS’s 2020 target. This leads to demand of efavirenz drug and consequently the market is expected to experience a significant growth during the forecast period. Moreover, as per the data of (UNAIDS), by the end of 2019, 25.4 million people with HIV (67%) were accessing antiretroviral therapy (ART) globally. It means 12.6 million people are still waiting. HIV treatment access is key to the global effort to end AIDS as a public health threat.  To eradicate HIV globally, there will be surge in production or manufacture of antiviral drugs, hence this propels growth of the efavirenz market.

New product launches to flourish the market

New products that contain improved capabilities have been launched by leading market players. In March 2018, global pharmaceutical company, Mylan announced launch of new HIV treatment symfi lo (efavirenz, lamivudine, and tenofovir disoproxil fumarate) 400 mg/300  and mg/300 mg tablets, which are taken once-daily, a single-tablet regimen (STR) and is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg.

Key segments covered

Segments

Subsegments

  Type

  • Single Efavirenz
  • Two-drug combination
  • Three-drug combination

  Application

  • Adults
  • Children

 End User

  • Hospitals
  • Clinics
  • Others

 

Key benefits of the report

  • This study presents the analytical depiction of the global efavirenz market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the efavirenz market share.
  • The current market is quantitatively analyzed from 2020 to 2030 to highlight the efavirenz market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the efavirenz market. 
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.  

Questions answered in the efavirenz market report 

  • Which are the leading players active in the efavirenz market? 
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the projections for the future that would help in taking further strategic steps?
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
PURCHASE OPTIONS

Start reading ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
Allied Market Research Allied Market Research Allied Market Research

Access from any device, anywhere

Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.

RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

REQUEST TOC/SAMPLE

OR

Purchase Full Report of
Efavirenz Market

Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456  $3,110
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840  $3,456
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769  $5,192
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450  $5,805
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $9,995  $8,996
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers